Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1930-1937

  Ayala Breton, Camilo ^a   Suksanpaisan, Lukkana ^a   Mader, Emily K ^a   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MATRIX PROTEIN; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; PROTEIN M51; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL FUSION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEASLES VIRUS; MOUSE; MULTIPLE MYELOMA; NEUROTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; SINGLE DRUG DOSE; TUMOR CELL; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIGENS, CD46; BRAIN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MEASLES VIRUS; MICE; MICE, SCID; MICE, TRANSGENIC; MULTIPLE MYELOMA; NEURONS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VERO CELLS; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885023559     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.164     Document Type: Article

References (50)

1. Blackham, AU, Northrup, SA, Willingham, M, D'Agostino, RB Jr, Lyles, DS and Stewart, JH 4th (2013). Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery 153: 333-343.
2. Naik, S, Nace, R, Barber, GN and Russell, SJ (2012). Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-ß. Cancer Gene Ther 19: 443-450.
3. Murphy, AM, Besmer, DM, Moerdyk-Schauwecker, M, Moestl, N, Ornelles, DA, Mukherjee, P et al. (2012). Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol 86: 3073-3087.
4. Heiber, JF and Barber, GN (2011). Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol 85: 10440-10450.
5. Le Boeuf, F, Niknejad, N, Wang, J, Auer, R, Weberpals, JI, Bell, JC et al. (2012). Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. Int J Cancer 131: E204-E215.
6. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
7. Barber, GN (2004). Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17: 516-527.
8. Bi, Z, Barna, M, Komatsu, T and Reiss, CS (1995). Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 69: 6466-6472.
9. Black, BL, Rhodes, RB, McKenzie, M and Lyles, DS (1993). The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J Virol 67: 4814-4821.
10. Ahmed, M, McKenzie, MO, Puckett, S, Hojnacki, M, Poliquin, L and Lyles, DS (2003). Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77: 4646-4657.
11. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
12. Ahmed, M, Cramer, SD and Lyles, DS (2004). Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330: 34-49.
13. Obuchi, M, Fernandez, M and Barber, GN (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 77: 8843-8856.
14. Shou, J, Soriano, R, Hayward, SW, Cunha, GR, Williams, PM and Gao, WQ (2002). Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 99: 2830-2835.
15. Saloura, V, Wang, LC, Fridlender, ZG, Sun, J, Cheng, G, Kapoor, V et al. (2010). Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther 21: 51-64.
16. Matin, SF, Rackley, RR, Sadhukhan, PC, Kim, MS, Novick, AC and Bandyopadhyay, SK (2001). Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res 61: 2261-2266.
17. Fishelson, Z, Donin, N, Zell, S, Schultz, S and Kirschfink, M (2003). Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40: 109-123.
18. Anderson, BD, Nakamura, T, Russell, SJ and Peng, KW (2004). High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64: 4919-4926.
19. Galanis, E (2010). Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 88: 620-625.
20. Galanis, E, Hartmann, LC, Cliby, WA, Long, HJ, Peethambaram, PP, Barrette, BA et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70: 875-882.
21. Ayala-Breton, C, Barber, GN, Russell, SJ and Peng, KW (2012). Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 23: 484-491.
22. Sabin, AB and Olitsky, PK (1938). Influence of host factors on neuroinvasiveness of vesicular stomatitis virus: IV. Variations in neuroinvasiveness in difierent species. J Exp Med 67: 229-249.
23. Kemper, C, Leung, M, Stephensen, CB, Pinkert, CA, Liszewski, MK, Cattaneo, R et al. (2001). Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin Exp Immunol 124: 180-189.
24. Buchholz, CJ, Gerlier, D, Hu, A, Cathomen, T, Liszewski, MK, Atkinson, JP et al. (1996). Selective expression of a subset of measles virus receptor-competent CD46 isoforms in human brain. Virology 217: 349-355.
25. Mrkic, B, Pavlovic, J, Rülicke, T, Volpe, P, Buchholz, CJ, Hourcade, D et al. (1998). Measles virus spread and pathogenesis in genetically modified mice. J Virol 72: 7420-7427.
26. Dingli, D, Peng, KW, Harvey, ME, Greipp, PR, O'Connor, MK, Cattaneo, R et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646.
27. Myers, RM, Greiner, SM, Harvey, ME, Griesmann, G, Kuffel, MJ, Buhrow, SA et al. (2007). Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 82: 700-710.
28. Goel, A, Carlson, SK, Classic, KL, Greiner, S, Naik, S, Power, AT et al. (2007). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)- NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110: 2342-2350.
29. Noyce, RS, Bondre, DG, Ha, MN, Lin, LT, Sisson, G, Tsao, MS et al. (2011). Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 7: e1002240.
30. Dörig, RE, Marcil, A, Chopra, A and Richardson, CD (1993). The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295-305.
31. Naniche, D, Varior-Krishnan, G, Cervoni, F, Wild, TF, Rossi, B, Rabourdin-Combe, C et al. (1993). Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67: 6025-6032.
32. Mühlebach, MD, Mateo, M, Sinn, PL, Prüfer, S, Uhlig, KM, Leonard, VH et al. (2011). Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480: 530-533.
33. Tatsuo, H, Ono, N, Tanaka, K and Yanagi, Y (2000). SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893-897.
34. Ong, HT, Timm, MM, Greipp, PR, Witzig, TE, Dispenzieri, A, Russell, SJ et al. (2006). Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 34: 713-720.
35. Schnell, MJ, Buonocore, L, Kretzschmar, E, Johnson, E and Rose, JK (1996). Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 93: 11359-11365.
36. Cureton, DK, Massol, RH, Saffarian, S, Kirchhausen, TL and Whelan, SP (2009). Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog 5: e1000394.
37. Liu, C, Hasegawa, K, Russell, SJ, Sadelain, M and Peng, KW (2009). Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 69: 1128-1141.
38. Hasegawa, K, Nakamura, T, Harvey, M, Ikeda, Y, Oberg, A, Figini, M et al. (2006). The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12(20 Pt 1): 6170-6178.
39. Paraskevakou, G, Allen, C, Nakamura, T, Zollman, P, James, CD, Peng, KW et al. (2007). Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther 15: 677-686.
40. Bergman, I, Whitaker-Dowling, P, Gao, Y and Griffin, JA (2004). Preferential targeting of vesicular stomatitis virus to breast cancer cells. Virology 330: 24-33.
41. Dingli, D, Peng, KW, Harvey, ME, Vongpunsawad, S, Bergert, ER, Kyle, RA et al. (2005). Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 337: 22-29.
42. Tesfay, MZ, Kirk, AC, Hadac, EM, Griesmann, GE, Federspiel, MJ, Barber, GN et al. (2013). PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol 87: 3752-3759.
43. Willmon, C, Harrington, K, Kottke, T, Prestwich, R, Melcher, A and Vile, R (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 17: 1667-1676.
44. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
45. Browder, T, Butterfield, CE, Kräling, BM, Shi, B, Marshall, B, O'Reilly, MS et al. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886.
46. Liu, C, Russell, SJ and Peng, KW (2010). Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 18: 1155-1164.
47. Nakamura, T, Peng, KW, Vongpunsawad, S, Harvey, M, Mizuguchi, H, Hayakawa, T et al. (2004). Antibody-targeted cell fusion. Nat Biotechnol 22: 331-336.
48. Lawson, ND, Stillman, EA, Whitt, MA and Rose, JK (1995). Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92: 4477-4481.
49. Hadac, EM, Peng, KW, Nakamura, T and Russell, SJ (2004). Reengineering paramyxovirus tropism. Virology 329: 217-225.
50. Jenks, N, Myers, R, Greiner, SM, Thompson, J, Mader, EK, Greenslade, A et al. (2010). Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 21: 451-462.